Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. - Wikidata - awgldk - TriplyDB

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

http://www.wikidata.org/entity/Q39654887

about

Natural killer cells in human cancer: from biological functions to clinical applications Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.Incidence and risk of severe neutropenia in advanced cancer patients treated with cetuximab: a meta-analysis Immunology and immunotherapy of neuroblastoma Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis.Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.Lenalidomide in solid tumors.Lenalidomide in multiple myeloma: Current status and future potential.Combination strategies to enhance antitumor ADCC.Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity Targeted therapies for cutaneous T-cell lymphomas.Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer.Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions.Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.Molecular action of lenalidomide in lymphocytes and hematologic malignancies Trial Watch: Lenalidomide-based immunochemotherapy.How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.Lenalidomide improvement of cisplatin antitumor efficacy on triple-negative breast cancer cells in vitro.

P2860

Q27691427-D1D5A759-5D97-426C-ADCE-36395C814CC7 Q28534997-64063BEB-3BA5-4F52-99DB-D18D12B47A5E Q33421680-7D8675D1-8915-4E52-8743-B9B08417D026 Q33429608-920EC3C0-FC2C-4234-A2FD-0444DC66D72C Q33597441-7A21AE13-F5F5-4EFE-8A22-B8C76539732B Q33940675-406162F7-70E3-460F-B5CE-005F75EB0D63 Q35669068-5B04A3A2-6A91-42BD-8127-6D240D53B9A2 Q36190723-5FC683AF-4AB0-478D-B9C2-58733353914A Q36252792-8EA836FD-61B1-4679-8C19-8E20479BB469 Q36377940-123AC227-8C26-4BE1-8531-F049B6EE649B Q36542800-C9996D50-E386-400B-9651-401B52C56876 Q36649908-F219C2AC-ABD5-4CC9-9C75-5F73AC6CF42B Q36856798-47C11964-516D-45AD-9157-E8080EB4EA7B Q36980961-CDC38EBF-631B-4EDF-BC81-94CBEF8E01F1 Q37535365-E0030E90-BB58-4149-9756-6DF7A2FAA64D Q37557880-51863183-87EA-449A-818C-3FDA56B6BE16 Q37683033-600DCC22-3015-4A5C-996F-60F4265F4598 Q37919717-119D7C17-A3A5-42FA-ADCC-2C369BBEF870 Q38010055-BDBC8E9D-7728-478A-9EED-F1BFF4463727 Q38013995-2A0A927F-EB32-4067-B562-9A04689AD4A4 Q38014085-40E2D92A-7153-4DD2-8E08-753A6CF24821 Q38203261-9015E20D-19AF-40B0-8B86-F422ACA69D6E Q38229634-AC161B53-E52F-46C9-944D-FE0323FF7266 Q38240998-72603186-0D92-47C1-918E-3F722DD9FA6E Q38542034-49AE6E44-9805-421A-99C1-43514BFA886E Q38670280-194E5FFB-F822-40B5-A1D1-B406E2F833DE Q39062237-47448CD0-DF1E-443E-82B1-785F3918DD9D Q39570166-2BB30C17-DBAE-493E-96F2-8A67309D7D3E Q42737828-27832087-0495-453E-8E99-84409201DB3D Q52668325-CA269F5F-F94D-4EA1-AFCD-7AFD3C4FD663 Q54117845-4AE0BC81-8EB0-4C7B-B22B-C90EE8610F9A

P2860

Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.

http://www.wikidata.org/entity/Q39654887

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Lenalidomide enhances antibody ...... host immune and tumor markers.

@en

Lenalidomide enhances antibody ...... host immune and tumor markers.

@nl

type

label

Lenalidomide enhances antibody ...... host immune and tumor markers.

@en

Lenalidomide enhances antibody ...... host immune and tumor markers.

@nl

prefLabel

Lenalidomide enhances antibody ...... host immune and tumor markers.

@en

Lenalidomide enhances antibody ...... host immune and tumor markers.

@nl

P1433

Q39654887-7F29B50E-1726-4600-B55A-FCBD17C15839

P1476

Q39654887-A09463E7-6E93-4545-AF29-B826EE1EBBE6

P2093

Q39654887-47BEB24C-F590-449B-901A-677A9F3291F3

Q39654887-4C574315-5E6E-4EA7-AE9F-54AC1E583098

Q39654887-5E12E327-99C8-42D1-BBFD-C1E7F36C022A

Q39654887-6FB32B36-D7C1-4185-A964-4A3AA233161B

Q39654887-C4A1E61F-F15B-403E-B3AC-6F6EA7257A27

Q39654887-F844F027-3BF6-4DC7-BF2B-1862F9788FE5

P2860

Q39654887-0CA173FF-D02C-4FD2-854F-802272F39F3C

Q39654887-0CE43F9B-A739-4A39-9F39-A86724A889FB

Q39654887-123DEC73-4B27-4EE1-AED0-8A6B1AF70C3F

Q39654887-17F89483-2BBF-4BE8-8037-FC30984C5E94

Q39654887-20D8CB6E-5CD6-4F74-9A5D-1F3A86363476

Q39654887-2B2526F3-579A-4619-87B6-4E57121C3C7F

Q39654887-3B4FC0B9-3D6D-4071-83F4-0A8728BF9AF0

Q39654887-4F1E90BC-A963-4B2A-BD9B-2C04F7B27F52

Q39654887-5884376A-0F46-44A8-B7C2-D5677F2F9BC4

Q39654887-773E213F-CC37-4DB4-886D-F87BB8667467

P2888

Q39654887-1796AE50-E3E7-464B-BA2F-D5EE52AD0B20

P304

Q39654887-BB732617-4120-49D9-A830-B2BB9C5F2644

P31

Q39654887-04F9F10C-6978-4B57-927C-A972EE8AF968

P356

Q39654887-DBD09C99-3D30-43B4-9CB0-ED15B4387C68

P433

Q39654887-45F4987E-0396-4332-B0D8-4733885FEE62

P478

Q39654887-7EB7BA51-2C45-412F-B70C-770FFE9F2FB7

P577

Q39654887-14436E86-3D07-4EB4-87FD-B735B71E1CEB

P698

Q39654887-6F6903A4-BC28-45B6-89DE-FF9D7F315EB7

P921

Q39654887-9457AFCF-0E16-4E6E-8A80-EFE535BE61B4

Q39654887-DE43B89C-550A-4035-840B-BA025B0E9675

P356

S00262-010-0919-9

P1433

Cancer Immunology, Immunotherapy

P1476

Lenalidomide enhances antibody ...... host immune and tumor markers.

@en

P2093

Anastasia Parton

http://www.w3.org/2001/XMLSchema#string

J Blake Bartlett

http://www.w3.org/2001/XMLSchema#string

Lei Wu

http://www.w3.org/2001/XMLSchema#string

Ling Lu

http://www.w3.org/2001/XMLSchema#string

Mary Adams

http://www.w3.org/2001/XMLSchema#string

Peter Schafer

http://www.w3.org/2001/XMLSchema#string

P2860

Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells

Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.

NK cells and cancer.

P2888

s00262-010-0919-9

P304

61-73

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-010-0919-9

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20848094

http://www.w3.org/2001/XMLSchema#string

P921